Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: Potentiation by low-level depolarization

Journal of Neurochemistry

Volumn 109, Issue 4, 2009, Pages 1118-1128

  Guerreiro, Serge ^b,c   Ponceau, Aurélie ^b,c   Toulorge, Damien ^b,c   Martin, Elodie ^b,c   Alvarez Fischer, Daniel ^b,c   Hirsch, Etienne C ^b,c   Michel, Patrick P ^a,b,c,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Calcium; Dopaminergic; Oxidative stress; Parkinson; Uric acid

Indexed keywords

CALCIUM CHANNEL L TYPE; CATALASE; DEFEROXAMINE; DIHYDRORHODAMINE 123; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; POTASSIUM; PURINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TROLOX C; URIC ACID;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL REACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEPOLARIZATION; DOPAMINERGIC NERVE CELL; EMBRYO; FENTON REACTION; FLUORESCENCE; IRON CHELATION; LIPID PEROXIDATION; LONG TERM POTENTIATION; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PURINE METABOLISM; RAT; STRUCTURE ACTIVITY RELATION; URIC ACID BLOOD LEVEL;

ANIMALS; BLOTTING, WESTERN; CALCIUM; CELL POLARITY; CELLS, CULTURED; CYTOSOL; DOPAMINE; ELECTROPHYSIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; MESENCEPHALON; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; POTASSIUM; PURINES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; THYMIDINE; URIC ACID;

EID: 65649126049     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06040.x     Document Type: Article

References (40)

1. Agid Y. (1991) Parkinson's disease: pathophysiology. Lancet 337, 1321 1324.
2. Allameh A., Maleklou N., Zargari M. Sanati M. H. (2008) The influence of uric acid treatments on liver glutathione system prevent oxidative damages in experimental autoimmune encephalomyelitis mice. Neurosci. Lett. 439, 111 115.
3. Alonso A., Rodríguez L. A., Logroscino G. Hernán M. A. (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69, 1696 1700. (Pubitemid 350287126)
4. Alvarez-Fischer D., Guerreiro S., Hunot S., Saurini F., Marien M., Sokoloff P., Hirsch E. C., Hartmann A. Michel P. P. (2008) Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J. Neurochem. 107, 701 711.
5. Ames B. N., Cathcart R., Schwiers E. Hochstein P. (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl Acad. Sci. USA 78, 6858 6862. (Pubitemid 12216861)
6. Bharath S., Hsu M., Kaur D., Rajagopalan S. Andersen J. K. (2002) Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64, 1037 1048. (Pubitemid 35232279)
7. Buettner G. R. (1993) The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 300, 535 543. (Pubitemid 23232908)
8. Church W. H. Ward V. L. (1993) Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 33, 419 425.
9. Daadi M. M. Weiss S. (1999) Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. J. Neurosci. 19, 4484 4497. (Pubitemid 29241099)
10. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909. (Pubitemid 37130207)
11. Davies K. J., Sevanian A., Muakkassah-Kelly S. F. Hochstein P. (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem. J. 235, 747 754. (Pubitemid 16071985)
12. Du Y., Chen C. P., Tseng C. Y., Eisenberg Y. Firestein B. L. (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55, 463 472. (Pubitemid 46383176)
13. Duan W., Ladenheim B., Cutler R. G., Kruman I. I., Cadet J. L. Mattson M. P. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80, 101 110. (Pubitemid 34614582)
14. Duarte A. I., Santos M. S., Oliveira C. R. Rego A. C. (2005) Insulin neuroprotection against oxidative stress in cortical neurons: involvement of uric acid and glutathione antioxidant defenses. Free Radic. Biol. Med. 39, 876 889. (Pubitemid 43316941)
15. Endou H. Anzai N. (2008) Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 27, 578 584.
16. Fitzmaurice P. S., Ang L., Guttman M., Rajput A. H., Furukawa Y. Kish S. J. (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov. Disord. 18, 969 976. (Pubitemid 37185203)
17. Gao X., Chen H., Choi H. K., Curhan G., Schwarzschild M. A. Ascherio A. (2008) Diet, urate, and Parkinson's disease risk in men. Am. J. Epidemiol. 167, 831 838.
18. Guerreiro S., Toulorge D., Hirsch E., Marien M., Sokoloff P. Michel P. P. (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol. Pharmacol. 74, 980 989.
19. Haberman F., Tang S. C., Arumugam T. V., Hyun D. H., Yu Q. S., Cutler R. G., Guo Z., Holloway H. W., Greig N. H. Mattson M. P. (2007) Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromol. Med. 9, 315 323. (Pubitemid 350242634)
20. Halliwell B. Gutteridge J. M. (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1 14. (Pubitemid 14171443)
21. Hirsch E. C. (1992) Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32, S88 S93.
22. Jenner P. Olanow C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72 S84. (Pubitemid 28423832)
23. Keller J. N., Kindy M. S., Holtsberg F. W., St Clair D. K., Yen H. C., Germeyer A., Steiner S. M., Bruce-Keller A. J., Hutchins J. B. Mattson M. P. (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci. 18, 687 697. (Pubitemid 28041905)
24. de Lau L. M., Koudstaal P. J., Hofman A. Breteler M. M. (2005) Serum uric acid levels and the risk of Parkinson disease. Ann. Neurol. 58, 797 800. (Pubitemid 41552559)
25. Michel P. P., Alvarez-Fischer D., Guerreiro S., Hild A., Hartmann A. Hirsch E. C. (2007) Role of activity-dependent mechanisms in the control of dopaminergic neuron survival. J. Neurochem. 101, 289 297. (Pubitemid 46525286)
26. Muraoka S. Miura T. (2003) Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol. Toxicol. 93, 284 289. (Pubitemid 38096107)
27. Osborne P. G. Hashimoto M. (2006) Brain antioxidant levels in hamsters during hibernation, arousal and cenothermia. Behav. Brain Res. 168, 208 214. (Pubitemid 43201937)
28. Petroske E., Meredith G. E., Callen S., Totterdell S. Lau Y. S. (2001) Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106, 589 601. (Pubitemid 32925247)
29. Rodríguez-Martín E., Casarejos M. J., Canals S., De Bernardo S. Mena M. A. (2002) Thiolic antioxidants protect from nitric oxide-induced toxicity in fetal midbrain cultures. Neuropharmacology 43, 877 888. (Pubitemid 35217726)
30. Rodwell V. W. (1993) Metabolism of purines and pyrimidine nucleotides, in Harper's Biochemistry (Murray R. K., Granner D. K., Mayes P. A. Rodwell V W., eds), pp., 363 377. Appleton and Lange, London.
31. Salthun-Lassalle B., Hirsch E. C., Wolfart J., Ruberg M. Michel P. P. (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J. Neurosci. 24, 5922 5930. (Pubitemid 38859390)
32. Schiess M. Oh I. (2008) Serum uric acid and clinical progression in Parkinson disease: potential biomarker for nigrostriatal failure. Arch. Neurol. 65, 698 699.
33. Schwarzschild M. A., Schwid S. R., Marek K. et al. Parkinson Study Group PRECEPT Investigators 2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson's disease. Arch. Neurol. 65, 716 723.
34. Traver S., Salthun-Lassalle B., Marien M., Hirsch E. C., Colpaert F. Michel P. P. (2005) The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol. Pharmacol. 67, 1882 1891. (Pubitemid 41007770)
35. Traver S., Marien M., Martin E., Hirsch E. C. Michel P. P. (2006) The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol. Pharmacol. 70, 30 40. (Pubitemid 43920793)
36. 1/2) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol. Pharmacol. 62, 1043 1052. (Pubitemid 35222494)
37. Weisskopf M. G., O'Reilly E., Chen H., Schwarzschild M. A. Ascherio A. (2007) Plasma urate and risk of Parkinson's disease. Am. J. Epidemiol. 166, 561 567. (Pubitemid 47283643)
38. Whiteman M. Halliwell B. (1996) Protection against peroxynitrite- dependent tyrosine nitration and alpha 1-antiproteinase inactivation by ascorbic acid. A comparison with other biological antioxidants. Free Radic. Res. 25, 275 283. (Pubitemid 26356530)
39. Yu Z. F., Bruce-Keller A. J., Goodman Y. Mattson M. P. (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res. 53, 613 625. (Pubitemid 28380802)
40. Zhuang S. Schnellmann R. G. (2006) A death-promoting role for extracellular signal-regulated kinase. J. Pharmacol. Exp. Ther. 319, 991 997.